Fresh Tracks Therapeutics, Inc. (BBI) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.4 k

Shareholding (Dec 2023)

FII

0.01%

Held by 2 FIIs

DII

98.83%

Held by 1 DIIs

Promoter

0.00%

How big is Fresh Tracks Therapeutics, Inc.?

22-Jun-2025

As of Feb 28, Fresh Tracks Therapeutics, Inc. has a market capitalization of 5.58 million, with net sales of 8.00 million and a net profit of -5.89 million over the last four quarters. As of December 2023, the company has total assets of 11.59 million and shareholder's funds of 9.93 million.

What does Fresh Tracks Therapeutics, Inc. do?

22-Jun-2025

Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapeutics for skin diseases, with a market cap of $5.58 million and a recent net profit of -$1 million. The company operates in the micro-cap sector and has key financial metrics indicating significant losses and a high dividend yield.

Who are in the management team of Fresh Tracks Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Fresh Tracks Therapeutics, Inc. includes Chairman and Co-Founder Reginald Hardy, CEO and Director Robert Brown, and Directors Gary Lyons, Vijay Samant, and Dennison Veru, who oversee the company's strategic direction and operations.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals: Major

Market cap

USD 6 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

4,939.99%

Debt Equity

-1.09

Return on Equity

-59.33%

Price to Book

0.56

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2023)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

29.86%

6 Months

29.86%

1 Year

3.09%

2 Years

-47.77%

3 Years

345.24%

4 Years

-21.43%

5 Years

-68.09%

Fresh Tracks Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

37.66%

EBIT Growth (5y)

10.70%

EBIT to Interest (avg)

-21.63

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.09

Sales to Capital Employed (avg)

0.45

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

11.42%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.56

EV to EBIT

0.83

EV to EBITDA

0.84

EV to Capital Employed

5.28

EV to Sales

-0.66

PEG Ratio

Dividend Yield

4939.99%

ROCE (Latest)

636.00%

ROE (Latest)

-59.33%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (1.16%)

Foreign Institutions

Held by 2 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2023 is -100.00% vs 7,800.00% in Sep 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2023 is -163.16% vs 182.61% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "7.90",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.60",
          "val2": "2.00",
          "chgp": "-180.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.20",
          "val2": "1.90",
          "chgp": "-163.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "251.40%",
          "chgp": "-25.14%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 15.94% vs 1,625.00% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 72.99% vs 46.58% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.00",
          "val2": "6.90",
          "chgp": "15.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.30",
          "val2": "-21.40",
          "chgp": "70.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.70",
          "val2": "-21.10",
          "chgp": "72.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-794.40%",
          "val2": "-3,101.50%",
          "chgp": "230.71%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQ

Dec'23

Sep'23

Change(%)

Net Sales

0.00

7.90

-100.00%

Operating Profit (PBDIT) excl Other Income

-1.60

2.00

-180.00%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-1.20

1.90

-163.16%

Operating Profit Margin (Excl OI)

0.00%

251.40%

-25.14%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2023 is -100.00% vs 7,800.00% in Sep 2023

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2023 is -163.16% vs 182.61% in Sep 2023

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'23

Dec'23

Dec'22

Change(%)

Net Sales

8.00

6.90

15.94%

Operating Profit (PBDIT) excl Other Income

-6.30

-21.40

70.56%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-5.70

-21.10

72.99%

Operating Profit Margin (Excl OI)

-794.40%

-3,101.50%

230.71%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2023 is 15.94% vs 1,625.00% in Dec 2022

Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 72.99% vs 46.58% in Dec 2022

All Annual Results

Company CV

About Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc.

Pharmaceuticals: Major

Brickell Biotech, Inc., formerly Vical Incorporated, is a clinical-stage pharmaceutical company that focuses on the development of therapeutics for the treatment of skin diseases. The Company’s pipeline consists of molecular entities targeting the treatment of the indications, such as hyperhidrosis, cutaneous T-cell lymphoma, allergic contact dermatitis, psoriasis and androgenic alopecia. The Company’s product candidates include BBI-3000, BBI-6000 and Sofpironium Bromide. Sofpironium Bromide is a topical soft anticholinergic for axillary hyperhidrosis. BBI-3000 is an oral rexinoid for cutaneous T-cell lymphoma. BBI-6000 is a retinoic acid-related orphan nuclear receptor gamma antagonist, which is develops for psoriasis.

Company Coordinates

Company Details

5777 Central Ave Ste 102 , BOULDER CO : 80301-2870

Tel: 1 720 5054755

https://brickellbio.com/

Registrar Details

Fresh Tracks Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Fresh Tracks Therapeutics, Inc.?

Watch in Real-Time

What does Fresh Tracks Therapeutics, Inc. do?

Who are in the management team of Fresh Tracks Therapeutics, Inc.?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQ

Annual Results Snapshot (Consolidated) - Dec'23

About Fresh Tracks Therapeutics, Inc.

Company Coordinates